Just saw that Organon got FDA approval for VTAMA cream treating pediatric eczema down to age 2, and the Phase 3 data is pretty solid—kids showed sleep improvements as early as week one. The thing is, sleep disruption in atopic dermatitis is actually huge for families, so a prescription-strength cream that addresses that specific burden could be a game changer. They tested it on 654 pediatric patients and the results held steady through week 8 across different age groups. Stock barely moved 0.8% on the news though, which seems like the market's still catching up. Makes you wonder if this kind of patient-outcome focused data will shift how dermatologists prescribe going forward? The atopic dermatitis market itself is projected to grow around 7-8% annually, so the timing seems decent.